Krakow, Poland – 6 March 2020 – Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced today an update on the progress of Phase I clinical trial for SEL24/MEN1703 – orally available, dual PIM/FLT3 kinase inhibitor for the treatment of acute myeloid leukemia (AML).
Based on the information received from Berlin-Chemie, part of the Menarini Group, the sole sponsor of SEL24/MEN1703 clinical trial, Phase I dose escalation study was successfully completed with the establishment of the recommended dose for Phase II studies of the drug. The Menarini Group plans to continue the study in Phase II (cohort expansion) at the recommended dose level.
More details regarding Phase I study results will be disclosed by Menarini at the upcoming scientific conferences.
According to the terms of the license agreement between Ryvu and Berlin Chemie, first development milestone has been reached and Ryvu is eligible to receive €1.75 M milestone payment.
SEL24/MEN1703 is a clinical stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. SEL24/MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address disease that has progressed following FLT3 inhibition. SEL24/MEN1703 is initially being developed for the treatment of patients with relapsed/refractory acute myeloid leukemia. Preclinical data suggests therapeutic potential in other hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize SEL24/MEN1703.
More information on the study at: https://clinicaltrials.gov/ct2/show/NCT03008187